Implementation of an Empiric Transfusion Bundle for Out of Hospital Patients With Haemorrhagic Shock

Launched by MEDICAL UNIVERSITY OF GRAZ · Mar 17, 2025

Keywords

ClinConnect Summary

This clinical trial is designed to look at a special treatment plan for patients experiencing severe bleeding due to trauma, known as hemorrhagic shock. The treatment plan includes giving patients a combination of fibrinogen (a protein that helps blood clot), plasma (the liquid part of blood), and tranexamic acid (a medicine that helps reduce bleeding). The goal is to see if this approach can improve outcomes for patients who are in critical condition.

To participate in this trial, you need to be at least 18 years old and have signs of life-threatening bleeding, which may include rapid heart rate, low blood pressure, or other signs that your body is not getting enough blood. However, if you have had a recent blood clotting issue, are pregnant, or have previously refused to take part in a clinical trial, you may not be eligible. If you join the trial, you will receive the treatment as part of your care, and your health will be closely monitored. This trial is currently not recruiting participants yet, but it aims to improve care for patients who are in critical need.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • aged, or believed to be aged
• • 18 years or above
• • confirmed or suspected life-threatening bleeding from trauma (i.e. signs of inadequate perfusion of tissues, tachycardia, hypotension, suspected blood loss)
• • need for volume replacement therapy.
• Exclusion Criteria:
• • patient with known recent history of thromboembolic events within the last 6 months
• • known or suspected pregnancy at presentation
• • patient with known refusal of a participation in this clinical trial.